AstraZeneca to Pay Up to $2 Billion for Obesity Pill as Weight Loss Drug Market Grows, FDA Approves Lilly's Drug, Zepbound to Make Drugs Cheaper

AstraZeneca is set to pay up to $2 billion for an experimental obesity pill as the weight loss drug market grows. The FDA has approved Lilly's weight loss drug. AstraZeneca raised its annual earnings forecast due to strong demand for its cancer drugs and a deal costing up to $2 billion in the anti-obesity market. Zepbound, Lilly's new Ozempic rival, is expected to make weight loss drugs cheaper. Ozempic is being used off-label as a weight loss drug, causing problems for diabetes patients. The introduction of new weight loss drugs is leading to a price war among drugmakers, and side effects may include a broken budget.